|
See related Vesanoid cap information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Tretinoin |
|
Indications |
Induction of remission in acute promyelocytic leukemia. |
|
Dosage |
A total daily dose of 45 mg/m2 body surface divided in 2 equal doses. Regimen should continue for 30-90 days. |
|
Administration |
Should be taken with food |
|
Contraindications |
Hypersensitivity. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Retinoic acid syndrome, xeroderma, mouth dryness, cheilitis, rash, edema, nausea, vomiting & bone pain.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs affecting the hepatic CYP450 enzyme system function may interact w/ all-trans retinoic acid, leading to change of blood levels; antifibrinolytic agents; agents known to cause intracranial HTN or pseudotumor cerebri eg tetracyclines; vit A.
View more drug interactions with Vesanoid |
|
Pregnancy Category (US FDA) |
 |
 |
 |
 |
 |
|
|
|
|
|
 |
|
|
|
Contraindicated in 1st trimester. |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01XX14 - tretinoin ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Vesanoid capsule |
|
|
|
Manufacturer: |
Roche |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
